A large number of antibodies to GLP-1 are listed in Biocompare but I have no personal experience with them
Vomiting and nausea are most common during the first 48 weeks of GLP-1 treatment and typically diminish as your body adapts to the medication
Complete data show tirzepatide, Lillys dual-action diabetes drug, brings greater A1C reduction, weight loss than semaglutide
Factors such as genetics, age, the amount of weight lost, and individual skin characteristics all play a role in how facial features are affected
GLP-1RAs, such as lixisenatide, not only rely on -cell function and glucagon suppression, but also assist to lower glucose by other (insulin-independent) mechanisms such as delayed gastric emptying, underlying the clinical utility of GLP-1RAs as adjuvant therapy to basal insulin in longstanding T2DM [14]
This phase of growth will be shaped by rapid expansion in treatment access through private insurance and self-pay channels, increasing clinical adoption for cardiovascular risk reduction, and growing physician confidence in long-term safety profiles
